NanoViricides (NNVC) 10-Q 9 Nov 15 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2015	Nov. 06, 2015
Document Information [Line Items]
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	1,379,006
Current Fiscal Year End Date	--06-30
Entity Filer Category	Accelerated Filer
Trading Symbol	NNVC
Entity Common Stock, Shares Outstanding		57,585,000
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,016

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2015	Jun. 30, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 29,480,258	$ 31,467,748
Prepaid expenses	163,493	214,425
Total Current Assets	29,643,751	31,682,173
PROPERTY AND EQUIPMENT
Property and equipment	13,830,515	13,496,851
Accumulated depreciation	(1,695,809)	(1,534,203)
Property and equipment, net	12,134,706	11,962,648
TRADEMARK
Trademark and patents	458,954	458,954
Accumulated amortization	(61,284)	(59,217)
Trademark and patents, net	397,670	399,737
OTHER ASSETS
Service agreements	123,082	142,531
Total Assets	42,299,209	44,187,089
CURRENT LIABILITIES:
Accounts payable	58,542	89,517
Accounts payable - related party	738,287	316,196
Accrued expenses	19,595	28,515
Deferred interest payable - current portion	166,667	166,667
Total Current Liabilities	983,091	600,895
Deferred interest payable - long term portion	291,666	333,333
Total Long Term Liabilities	10,604,388	11,800,327
Total Liabilities	$ 11,587,479	$ 12,401,222
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 150,000,000 shares authorized, 57,585,505 and 57,242,070 shares issued and outstanding, respectively	$ 57,585	$ 57,242
Additional paid-in capital	86,056,671	85,824,613
Accumulated deficit	(55,406,526)	(54,099,572)
Total Stockholders' Equity	30,711,730	31,785,867
Total Liabilities and Stockholders' Equity	42,299,209	44,187,089
Warrant [Member]
CURRENT LIABILITIES:
Derivative liability	2,475,893	3,442,754
Series B Debentures [Member]
CURRENT LIABILITIES:
Debenture subscription deposit	4,884,211	4,700,582
Derivative liability	82,503	366,764
Series C Debentures [Member]
CURRENT LIABILITIES:
Debenture subscription deposit	2,630,686	2,480,605
Derivative liability	239,429	476,289
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Series A Convertible Preferred stock, $0.001 par value, 4,000,000 shares designated, 4,000,000 and 3,583,445 shares issued and outstanding, respectively	$ 4,000	$ 3,584

Balance Sheets _Parenthetical_

Balance Sheets [Parenthetical] - $ / shares	Sep. 30, 2015	Jun. 30, 2015
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	57,585,505	57,242,070
Common stock, shares, outstanding	57,585,505	57,242,070
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, shares issued	4,000,000	3,583,445
Preferred stock, shares outstanding	4,000,000	3,583,445

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
OPERATING EXPENSES
Research and development	$ 1,282,072	$ 811,107
General and administrative	942,979	876,026
Total operating expenses	2,225,051	1,687,133
LOSS FROM OPERATIONS	(2,225,051)	(1,687,133)
OTHER INCOME (EXPENSE):
Interest income	8,825	39,323
Interest expense	(245,000)	(245,000)
Discount on convertible debentures	(333,710)	(273,218)
Change in fair value of derivatives	1,487,982	3,017,725
Other income, net	918,097	2,538,830
(LOSS) INCOME BEFORE INCOME TAXES	(1,306,954)	851,697
INCOME TAX PROVISION	0	0
NET (LOSS) INCOME	$ (1,306,954)	$ 851,697
NET (LOSS) INCOME PER COMMON SHARE
Basic (in dollars per share)	$ (0.02)	$ 0.02
Diluted (in dollars per share)	$ (0.02)	$ 0.02
Weighted average common shares outstanding
Basic (in shares)	57,274,315	55,576,200
Diluted (in shares)	57,274,315	55,576,200

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - 3 months ended Sep. 30, 2015 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series A Preferred Stock [Member]
Balance at Jun. 30, 2015	$ 31,785,867	$ 57,242	$ 85,824,613	$ (54,099,572)	$ 3,584
Balance (in shares) at Jun. 30, 2015		57,242,070			3,583,445
Common Shares issued for employee stock bonus	3,300	$ 1	3,299	0	$ 0
Common Shares issued for employee stock bonus (In Shares)		1,295			0
Series A Preferred Shares issued for employee stock compensation	182,522	$ 0	182,105	0	$ 417
Series A Preferred Shares issued for employee stock compensation (in shares)		0			416,555
Share issued for consulting and legal services rendered	27,000	$ 20	26,980	0	$ 0
Share issued for consulting and legal services rendered (in shares)		20,455			0
Warrants issued to Scientific Advisory Board	8,745	$ 0	8,745	0	$ 0
Common Shares issued for Directors fees	11,250	$ 9	11,241	0	$ 0
Common Shares issued for Directors fees (in shares)		8,530			0
Common Shares issued upon stock option exercise	0	$ 313	(313)	0	$ 0
Common Shares issued upon stock option exercise (in shares)		313,155			0
Net loss	(1,306,954)	$ 0	0	(1,306,954)	$ 0
Balance at Sep. 30, 2015	$ 30,711,730	$ 57,585	$ 86,056,670	$ (55,406,526)	$ 4,001
Balance (in shares) at Sep. 30, 2015		57,585,505			4,000,000

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (1,306,954)	$ 851,697
Adjustments to reconcile net (loss) income to net cash used in operating activities
Series A Preferred shares issued as compensation	182,522	72,980
Common shares issued as compensation and for services	41,550	38,250
Warrants granted to Scientific Advisory Board	8,745	22,292
Depreciation	161,606	51,332
Amortization	2,067	2,193
Change in fair value of derivative liability	(1,487,982)	(3,017,725)
Amortization of debt discount on convertible debentures	333,710	273,218
Changes in operating assets and liabilities:
Prepaid expenses	50,932	48,990
Other current assets	0	150,000
Other long term assets	19,449	0
Accounts payable	(30,975)	(220,468)
Accounts payable - related party	422,091	(142,409)
Accrued expenses	(8,920)	173,625
Deferred interest payable	(41,667)	0
NET CASH USED IN OPERATING ACTIVITIES	(1,653,826)	(1,696,025)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(333,664)	(562,512)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants	0	6,682,297
NET CHANGE IN CASH	(1,987,490)	4,423,760
Cash at beginning of period	31,467,748	36,696,892
Cash at end of period	29,480,258	41,120,652
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	286,667	245,000
Income tax paid	0	0
NON CASH FINANCING AND INVESTING ACTIVITIES:
Series A Preferred stock issued as discount on Debentures	0	1,646,606
Common Stock issued upon cashless exercise of stock options	$ 313	$ 0

Organization and Nature of Busi

Organization and Nature of Business	3 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Nature of Operations [Text Block]	Note 1 - Organization and Nature of Business NanoViricides, Inc. was incorporated under the laws of the State of Colorado July 25, 2000 Edot-com.com, Inc . May 12, 2005 ., On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricides, Nanoviricides, Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 100,000,000 4,000 As a result of the Exchange transaction, the former NVI stockholders held approximately 80 On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased. Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively. NanoViricides, Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and e-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010 the Company executed an Additional License Agreement with TheraCour. 2,000,000 (adjusted for the 3.5 to 1 reverse split) The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock. Series A 2,000,000 2,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015 filed on September 14, 2015. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2015 September 30, 2014 Stock options - 535,715 Warrants 5,993,823 5,925,231 Total potentially outstanding dilutive common shares 5,993,823 6,460,946 In addition, the Company has issued Convertible Debentures to investors. A portion of the interest required to be paid on the debentures had been paid in shares of the Company’s $ 0.001 571,428 At September 30, 2015, the number of potentially dilutive shares of the Company’s common stock into which the Series B debentures can be converted based upon the conversion price of $ 3.50 1,714,286 952,381 The Company has also issued 4,000,000 3.5 14,000,000 Pursuant to the redemption provisions of the Series C Debentures, the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the “Redemption Warrants”, and collectively with (i) – (iii), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act. For the three months ended September 30, September 30, 2015 2014 Calculation of basic loss per share of common stock: Net (loss) income attributable to common stockholders $ (1,306,954) $ 851,697 Denominator for basic weighted average shares of common stock 57,274,315 55,576,200 Basic (loss) income per share of common stock $ (0.02) $ 0.02 Calculation of diluted loss per share of common stock: Net (loss) income attributable to common stockholders $ (1,306,954) $ 851,697 Add: Income impact of assumed conversion of Debentures - - Net (loss) income attributable to common stockholders plus assumed conversions $ (1,306,954) $ 851,697 Denominator for basic weighted average shares of common stock 57,274,315 55,576,200 Incremental shares from assumed conversions of Debentures payable - - Denominator for diluted weighted average shares of common stock 57,274,315 55,576,200 Diluted (loss) income per share of common stock $ (0.02) $ 0.02 Series B and Series C debentures were excluded from the loss per share calculation for the three months ended September 30, 2015 because the impact is anti-dilutive. Series B Debentures were excluded from the income per share calculation for the three months ended September 30, 2014 because the impact is anti-dilutive. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-15 on the Company’s financial statements and disclosures. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30), “Simplifying the Presentation of Debt Issuance Costs,” which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for fiscal years beginning after December 15, 2015 and for interim periods within those fiscal years. We expect the adoption of this guidance will not have a material impact on our financial statements.

Financial Condition

Financial Condition	3 Months Ended
	Sep. 30, 2015
Financial Condition Disclosure [Abstract]
Financial Condition Disclosure [Text Block]	Note 3- Financial Condition The Company’s financial statements for the interim period ended September 30, 2015 have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company has a deficit accumulated from inception. In addition, the Company has not generated any revenues and no revenues are anticipated in the short-term. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of September 30, 2015 the Company had cash and cash equivalents of $ 29,480,258 While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities. The Company may require additional capital to finance currently unplanned capital costs and additional staffing requirements, if they arise, during the next 24 months. The Company has in the past adjusted its priorities and goals in line with the cash on hand and capital availability. The Company believes it can adjust its priorities of drug development and its plan of operations as necessary, if it is unable to raise additional funds.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 4 - Related Party Transactions Related Parties Related parties with whom the Company had transactions are: Related Parties Relationship Anil R. Diwan Chairman, President, significant stockholder and director Eugene Seymour CEO, Significant shareholder, Director TheraCour Pharma, Inc. An entity owned and controlled by a significant stockholder InnoHaven, LLC An entity owned and controlled by a significant stockholder Milton Boniuk, MD Director and significant stockholder Property and Equipment For the Three Months Ended September 30, September 30, 2015 2014 During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 7,901 $ 110,578 Account Payable – Related Party As of September 30, June 30, 2015 2015 Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was $ 738,287 $ 316,196 Research and Development Costs Paid to Related Parties For the three For the three months ended months ended September 30, September 30, 2015 2014 Development and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2015 and June 30, 2015. $ 1,016,216 $ 769,185 Long-Term Debentures Payable to a Director September 30, June 30, 2015 2015 Series B Convertible Debentures - Milton Boniuk $ 4,000,000 $ 4,000,000 Series C Convertible Debentures - Milton Boniuk 5,000,000 5,000,000 Total Long Term Debentures Payable to a Director $ 9,000,000 $ 9,000,000 September 30 June 30, Debenture Interest Paid to a Director 2015 2015 Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest will be paid out quarterly over the remaining term of the debenture commencing September 30, 2015: Deferred interest payable - short-term $ 166,667 $ 166,667 Deferred interest payable - long-term 291,666 333,333 Coupon interest expense on the Series B Debentures to Dr. Milton Boniuk for the three months ended September 30, 2015 and 2014 was $ 80,000 80,000 Coupon interest expense or recognized on Series C Debentures to Dr. Milton Boniuk for the three months ended September 30, 2015 and 2014 was $ 125,000 125,000

Property and Equipment

Property and Equipment	3 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 - Property and Equipment Property and equipment, stated at cost, less accumulated depreciation consisted of the following: September 30, June 30, 2015 2015 Land $ 260,000 $ 260,000 GMP Facility 7,979202 7,905,938 Office Equipment 65,621 65,241 Furniture and Fixtures 1,400 1,400 Lab Equipment 5,524,292 5,264,272 Total Property and Equipment 13,830,515 13,496,851 Less Accumulated Depreciation (1,695,809) (1,534,203) Property and Equipment, Net $ 12,134,706 $ 11,962,648 Depreciation expenses for the three months ended September 30, 2015 and 2014 were $ 161,606 51,332

Trademark and Patents

Trademark and Patents	3 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 - Trademark and Patents September 30, June 30, 2015 2015 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (61,284) (59,217) Trademarks and Patents, Net $ 397,670 $ 399,737 Amortization expense amounted to $ 2,067 2,193

Convertible Debentures

Convertible Debentures	3 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7 – Convertible Debentures On February 1, 2013, the Company raised gross proceeds of $ 6,000,000 4,000,000 4 8 571,429 571,429 3.50 3 3.50 The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a “shelf” registration statement provided same is available, in accordance with the provisions of the Securities Act. September 30, June 30, 2015 2015 Proceeds $ 6,000,000 $ 6,000,000 Debt discount for bifurcated derivative (2,735,310) (2,735,310) 3,264,690 3,264,690 Accumulated amortization of debt discount 1,619,521 1,435,892 Debenture payable - Series B, net $ 4,884,211 $ 4,700,582 The debenture contains embedded derivatives which are not clearly and closely related to the host instrument. The embedded derivatives are bifurcated from the host debt instrument and treated as a liability. The single compound embedded derivative features valued include the: 1. Principal conversion feature at maturity based on fixed conversion price subject to standard adjustments. 2. Redemption additional interest and Redemption Warrants offering. 3. Additional Interest Shares and Interest Warrants. For the three month period ended September 30, 2015 and 2014 the Company recognized amortization of this discount as an additional interest charge to “Discount on convertible debentures” in the amount of $ 183,629 157,728 The Company used a lattice model that values the compound embedded derivatives of the Series B Convertible Debenture based on a probability weighted discounted cash flow model at September 30, 2015 and June 30, 2015, respectively. The following assumptions were used for the valuation of the compound embedded derivative at September 30, 2015 and June 30, 2015: · The balance of the Series C Convertible Debenture as of September 30, 2015 and June 30, 2015 is $ 6,000,000 · The underlying stock price was used as the fair value of the common stock; The stock price decreased to $ 1.19 3.50 The stock price decreased to $ 1.75 3.50 · The projected annual volatility was based on the Company historical volatility: 1 year 9/30/2015 61.7 6/30/15 62% · An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% · The Company would redeem the debentures projected initially at 0 1.0 20.0 · The Holder would automatically convert the interest if the Company was not in default and its shares value would be equivalent to the cash value; · The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default. · The Weighted Cost of Capital discount rate (based on the Market Value of the transaction at issuance) adjusted for changes in the risk free rate is 21.60 · Even through the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The fair value of the compound embedded derivatives of the Series B Convertible Debenture at September 30, 2015 and June 30, 2015 was $ 82,503 366,764 On July 2, 2014 (the “Closing Date”), the Company accepted a subscription in the amount of $ 5,000,000 10 June 30, 2018 0.001 5.25 10 5.25 952,381 5.25 7 619,048 6.05 On July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 1,645,606 1,152,297 1,152,297 1,879,428 150,081 115,490 September 30, June 30, 2015 2015 Proceeds $ 5,000,000 $ 5,000,000 Debt Discount: Series A Preferred (1,152,297) (1,152,297) Embedded derivative (1,879,428) (1,879,428) 1,968,275 1,968,275 Accumulated amortization of debt discount 662,411 512,330 Debenture payable - Series C, net $ 2,630,686 $ 2,480,605 The Company used a lattice model that values the compound embedded derivatives of the Series C Convertible Debenture based on a probability weighted discounted cash flow model at September 30, 2015 and June 30, 2015. The following assumptions were used for the valuation of the compound embedded derivative at September 30, 2015 and June 30, 2015: · The balance of the Series C Convertible Debenture as of September 30, 2015 and June 30, 2015 is $ 5,000,000 · The underlying stock price was used as the fair value of the common stock; The stock price decreased to $ 1.19 6.05 1.75 6.05 · The projected annual volatility was based on the Company historical volatility: 1 year 9/30/2015 61.7 6/30/15 62% · An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% · The Company would redeem the debentures projected initially at 0 1.0 5.0 · The Holder would automatically convert the interest if the Company was not in default and its shares value was equivalent to the cash value; · The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default. · The weighted cost of capital discount rate (based on the market value of the transaction at issuance) adjusted for changes in the risk free rate is 21.60 % 21.97 · Even though the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The fair value of the compound embedded derivatives of the Series C Convertible Debenture at September 30, 2015 and June 30, 2015 was $ 239,429 476,289

Equity Transactions

Equity Transactions	3 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 8 - Equity Transactions On July 21, 2015, the Board of Directors approved a new employment agreement with Dr. Anil Diwan, the Company’s president. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 225,000 204,420 20,580 75,000 three years 77,336 On July 21, 2015, the Board of Directors approved a new employment agreement with Dr. Eugene Seymour, the Company’s Chief Executive Officer. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 225,000 204,420 20,580 75,000 three years 77,336 The Company estimated the fair value of the Series A Preferred stock granted to various employees and others on the date of grant. The Series A Preferred stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the holder would lose the voting rights upon conversion. The conversion of the shares is triggered by a Change of Control. The valuations of the Series A Preferred Stock at each issuance used the following inputs: a. The common stock price was in the range $ 1.11 1.75 b. The calculated weighted average number of shares of common stock in the period; c. A 5.36 d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 5.12 5.18 e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from March 1, 2013 for the Meeta Vyas issuances and a remaining restricted term of 1.59 1.42 f. The 7/21/15 Diwan & Seymour Preferred conversion value is based on the greater of the Change of Control in 4 years from 3/1/13 and the vesting on 6/30/16, 6/30/17, and 6/30/18 resulting in a remaining restricted term of 1.63 2.94 g. 27.74 39.78 60.40 62.21 0.27 0.39 In August, 2015, the Scientific Advisory Board (SAB) was granted fully vested warrants to purchase 17,148 1.50 August, 2019 8,745 For the three months ended September 30, 2015, the Company’s Board of Directors authorized the issuance of 7,716 27,850 For the three months ended September 30, 2015, the Company’s Board of Directors authorized the issuance of 1,295 3,300 For the three months ended September 30, 2015, the Company’s Board of Directors authorized the issuance of 20,455 27,000 For the three months ended September 30, 2015, the Company’s Board of Directors authorized the issuance of 8,530 11,250 The expense recognized by the Company upon issuance of restricted common shares for compensation or services is determined by the average market value of the Company’s common shares over the service period. The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) 4 Expected volatility 58.39 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.35 %

Stock Options and Warrants

Stock Options and Warrants	3 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 9 - Stock Options and Warrants Weighted Weighted Average Average Remaining Aggregate Number of Exercise Price Contractual Intrinsic Stock Options Shares per share ($) Term (years) Value ($) Outstanding and exercisable at June 30, 2015 535,715 $ 0.35 0.23 $ 2,094,643 Granted - - - - Exercised 428,573 - - - Expired 107,142 - - - Canceled - - - - Outstanding at September 30, 2015 - $ - - $ - Stock Warrants Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Warrants Shares ($) (years) ($) Outstanding and exercisable at June 30, 2015 5,976,675 $ 5.14 3.2 $ 19,000 Granted 17,148 1.5 3.75 - Exercised - - - Expired - - - Canceled - - - - Outstanding and exercisable at September 30,2015 5,993,823 $ 5.13 2.95 $ 4 Of the above warrants, 345,713 June 30, 2016 68,571 June 30, 2017 68,577 June 30, 2018 5,493,814 June 30, 2019 17,148 June 30, 2020

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 10 – Fair Value Measurement Fair value measurements At September 30, 2015 and June 30, 2015, the fair value of derivative liabilities is estimated using a lattice model that is based on the individual characteristics of our warrants, preferred and common stock, the derivative liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative liabilities are the only Level 3 fair value measures. Fair Value Measurements at September 30, 2015: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 82,503 Derivative liability – Series C debentures - - 239,429 Derivative liability – warrants - - 2,475,893 Total derivatives $ - $ - $ 2,797,825 Fair Value Measurements at June 30, 2015: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 366,764 Derivative liability – Series C debentures - - 476,289 Derivative liability – warrants - - 3,442,754 Total derivatives $ - $ - $ 4,285,808 In conjunction with the Company’s registered direct offerings of Units, consisting of the Company’s common stock and warrants, on September 12, 2013 and January 24, 2014 the Company issued 2,945,428 2,479,935 2,910,071 2,379,935 58,910 76,306 5,425,222 warrants outstanding and issued pursuant to the aforesaid registered direct offerings. The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to its own stock. The warrants described above contained a full-ratchet anti-dilution feature and are thus classified as a derivative liability. The Company used a lattice model to calculate the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise and full reset features. The Warrants were valued as of September 30, 2015 and June 30, 2015 with the following assumptions: - The 5 5.25 6.05 - The stock price would fluctuate with the Company projected volatility. - The Holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of 2 times 2 times - The next capital raise would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation periods. 1 Year 6/30/15 62% 9/30/15 62% The primary factors driving the economic value of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over the remaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assigned to each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option value was then probability weighted and discounted to the present. Fair Value Measurement Unobservable Inputs Derivative Derivative Derivative Beginning balance at July 1, 2015 $ 366,764 $ 476,289 $ 3,442,754 Additions during the year - - - Change in fair value (284,261) (236,860) (966,861) Transfer in and/or out of Level 3 - - - Balance at September 30, 2015 $ 82,503 $ 239,429 $ 2,475,893

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 11 - Commitments and Contingencies Operating Lease The Company completed the relocation of its laboratory and office from 135 Wood Street, West Haven, Connecticut to 1 Controls Drive, Shelton, Connecticut around June, 2015. The Company was renting 135 Wood Street on a month-to-month basis. Total rent expense at 135 Wood Street, West Haven, Connecticut amounted to $ 0 26,085 License Agreements The Company is dependent upon its license agreement with TheraCour Pharma, Inc. (See Note 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour Pharma license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates. Legal Proceedings There are no pending legal proceeding against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015 filed on September 14, 2015.
Earnings Per Share, Policy [Policy Text Block]	Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2015 September 30, 2014 Stock options - 535,715 Warrants 5,993,823 5,925,231 Total potentially outstanding dilutive common shares 5,993,823 6,460,946 In addition, the Company has issued Convertible Debentures to investors. A portion of the interest required to be paid on the debentures had been paid in shares of the Company’s $ 0.001 571,428 At September 30, 2015, the number of potentially dilutive shares of the Company’s common stock into which the Series B debentures can be converted based upon the conversion price of $ 3.50 1,714,286 952,381 The Company has also issued 4,000,000 3.5 14,000,000 Pursuant to the redemption provisions of the Series C Debentures, the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the “Redemption Warrants”, and collectively with (i) – (iii), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act. For the three months ended September 30, September 30, 2015 2014 Calculation of basic loss per share of common stock: Net (loss) income attributable to common stockholders $ (1,306,954) $ 851,697 Denominator for basic weighted average shares of common stock 57,274,315 55,576,200 Basic (loss) income per share of common stock $ (0.02) $ 0.02 Calculation of diluted loss per share of common stock: Net (loss) income attributable to common stockholders $ (1,306,954) $ 851,697 Add: Income impact of assumed conversion of Debentures - - Net (loss) income attributable to common stockholders plus assumed conversions $ (1,306,954) $ 851,697 Denominator for basic weighted average shares of common stock 57,274,315 55,576,200 Incremental shares from assumed conversions of Debentures payable - - Denominator for diluted weighted average shares of common stock 57,274,315 55,576,200 Diluted (loss) income per share of common stock $ (0.02) $ 0.02 Series B and Series C debentures were excluded from the loss per share calculation for the three months ended September 30, 2015 because the impact is anti-dilutive. Series B Debentures were excluded from the income per share calculation for the three months ended September 30, 2014 because the impact is anti-dilutive.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-15 on the Company’s financial statements and disclosures. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30), “Simplifying the Presentation of Debt Issuance Costs,” which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for fiscal years beginning after December 15, 2015 and for interim periods within those fiscal years. We expect the adoption of this guidance will not have a material impact on our financial statements.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2015 September 30, 2014 Stock options - 535,715 Warrants 5,993,823 5,925,231 Total potentially outstanding dilutive common shares 5,993,823 6,460,946 The following represents a reconciliation of the numerators and denominators of the basic and diluted per share calculations for (loss) income from continuing operations: For the three months ended September 30, September 30, 2015 2014 Calculation of basic loss per share of common stock: Net (loss) income attributable to common stockholders $ (1,306,954) $ 851,697 Denominator for basic weighted average shares of common stock 57,274,315 55,576,200 Basic (loss) income per share of common stock $ (0.02) $ 0.02 Calculation of diluted loss per share of common stock: Net (loss) income attributable to common stockholders $ (1,306,954) $ 851,697 Add: Income impact of assumed conversion of Debentures - - Net (loss) income attributable to common stockholders plus assumed conversions $ (1,306,954) $ 851,697 Denominator for basic weighted average shares of common stock 57,274,315 55,576,200 Incremental shares from assumed conversions of Debentures payable - - Denominator for diluted weighted average shares of common stock 57,274,315 55,576,200 Diluted (loss) income per share of common stock $ (0.02) $ 0.02

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Property and Equipment For the Three Months Ended September 30, September 30, 2015 2014 During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 7,901 $ 110,578 Account Payable – Related Party As of September 30, June 30, 2015 2015 Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was $ 738,287 $ 316,196 Research and Development Costs Paid to Related Parties For the three For the three months ended months ended September 30, September 30, 2015 2014 Development and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2015 and June 30, 2015. $ 1,016,216 $ 769,185 Long-Term Debentures Payable to a Director September 30, June 30, 2015 2015 Series B Convertible Debentures - Milton Boniuk $ 4,000,000 $ 4,000,000 Series C Convertible Debentures - Milton Boniuk 5,000,000 5,000,000 Total Long Term Debentures Payable to a Director $ 9,000,000 $ 9,000,000 September 30 June 30, Debenture Interest Paid to a Director 2015 2015 Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest will be paid out quarterly over the remaining term of the debenture commencing September 30, 2015: Deferred interest payable - short-term $ 166,667 $ 166,667 Deferred interest payable - long-term 291,666 333,333

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, less accumulated depreciation consisted of the following: September 30, June 30, 2015 2015 Land $ 260,000 $ 260,000 GMP Facility 7,979202 7,905,938 Office Equipment 65,621 65,241 Furniture and Fixtures 1,400 1,400 Lab Equipment 5,524,292 5,264,272 Total Property and Equipment 13,830,515 13,496,851 Less Accumulated Depreciation (1,695,809) (1,534,203) Property and Equipment, Net $ 12,134,706 $ 11,962,648

Trademark and Patents (Tables)

Trademark and Patents (Tables)	3 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, June 30, 2015 2015 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (61,284) (59,217) Trademarks and Patents, Net $ 397,670 $ 399,737

Convertible Debentures (Tables)

Convertible Debentures (Tables)	3 Months Ended
	Sep. 30, 2015
Series B Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following table presents the balance of the Series Debenture payable, net of discount at September 30, 2015 and June 30, 2015. The debt discount is being accreted to interest expense over the term of the debenture: September 30, June 30, 2015 2015 Proceeds $ 6,000,000 $ 6,000,000 Debt discount for bifurcated derivative (2,735,310) (2,735,310) 3,264,690 3,264,690 Accumulated amortization of debt discount 1,619,521 1,435,892 Debenture payable - Series B, net $ 4,884,211 $ 4,700,582
Series C Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following represents the balance of the Debenture payable – Series C, net of discount at September 30, 2015 and June 30, 2015: September 30, June 30, 2015 2015 Proceeds $ 5,000,000 $ 5,000,000 Debt Discount: Series A Preferred (1,152,297) (1,152,297) Embedded derivative (1,879,428) (1,879,428) 1,968,275 1,968,275 Accumulated amortization of debt discount 662,411 512,330 Debenture payable - Series C, net $ 2,630,686 $ 2,480,605

Equity Transactions (Tables)

Equity Transactions (Tables)	3 Months Ended
	Sep. 30, 2015
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) 4 Expected volatility 58.39 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.35 %

Stock Options and Warrants (Tab

Stock Options and Warrants (Tables)	3 Months Ended
	Sep. 30, 2015
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table presents the combined activity of stock options issued for the three months ended September 30, 2015 as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Price Contractual Intrinsic Stock Options Shares per share ($) Term (years) Value ($) Outstanding and exercisable at June 30, 2015 535,715 $ 0.35 0.23 $ 2,094,643 Granted - - - - Exercised 428,573 - - - Expired 107,142 - - - Canceled - - - - Outstanding at September 30, 2015 - $ - - $ -
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	As of September 30, 2015 there was no unrecognized compensation cost. Stock Warrants Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Warrants Shares ($) (years) ($) Outstanding and exercisable at June 30, 2015 5,976,675 $ 5.14 3.2 $ 19,000 Granted 17,148 1.5 3.75 - Exercised - - - Expired - - - Canceled - - - - Outstanding and exercisable at September 30,2015 5,993,823 $ 5.13 2.95 $ 4

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	At September 30, 2015 and June 30, 2015 the estimated fair values of the liabilities measured on a recurring basis are as follows: Fair Value Measurements at September 30, 2015: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 82,503 Derivative liability – Series C debentures - - 239,429 Derivative liability – warrants - - 2,475,893 Total derivatives $ - $ - $ 2,797,825 Fair Value Measurements at June 30, 2015: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 366,764 Derivative liability – Series C debentures - - 476,289 Derivative liability – warrants - - 3,442,754 Total derivatives $ - $ - $ 4,285,808
Schedule Of Projected Annual Volatility [Table Text Block]	The projected annual volatility for the valuation dates are: 1 Year 6/30/15 62% 9/30/15 62%
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended September 30, 2015: Fair Value Measurement Unobservable Inputs Derivative Derivative Derivative Beginning balance at July 1, 2015 $ 366,764 $ 476,289 $ 3,442,754 Additions during the year - - - Change in fair value (284,261) (236,860) (966,861) Transfer in and/or out of Level 3 - - - Balance at September 30, 2015 $ 82,503 $ 239,429 $ 2,475,893

Organization and Nature of Bu27

Organization and Nature of Business (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 15, 2010	Sep. 30, 2015	Jun. 30, 2015
Product Information [Line Items]
Entity Incorporation, State Country Name		Colorado
Entity Incorporation, Date Of Incorporation		Jul. 25, 2000
Business Acquisition, Name of Acquired Entity		Edot-com.com, Inc.
Business Acquisition, Date of Acquisition Agreement		May 12, 2005
Common stock, shares issued		57,585,505	57,242,070
Common stock, shares, outstanding		57,585,505	57,242,070
ECMM [Member]
Product Information [Line Items]
Common Stock Shares Issued Prorata Basis		4,000
Stock Issued During Period, Shares, New Issues		80,000,000
Common stock, shares issued		100,000,000
Common stock, shares, outstanding		100,000,000
Business Acquisition, Percentage of Voting Interests Acquired		80.00%
Series A Preferred Stock [Member]
Product Information [Line Items]
Preferred stock, shares issued	2,000,000
Series A Convertible Preferred stock, $0.001 par value, 4,100,000 shares designated, 4,041,161 and 3,583,445 shares issued and outstanding, respectively	$ 2,000
Convertible Preferred Stock, Terms of Conversion		The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Companys intellectual property, into shares of the Companys common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.
Stockholders' Equity, Reverse Stock Split	(adjusted for the 3.5 to 1 reverse split)

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details) - shares	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,993,823	6,460,946
Stock options [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	535,715
Warrants [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,993,823	5,925,231

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Calculation of basic loss per share of common stock:
Net (loss) income attributable to common stockholders	$ (1,306,954)	$ 851,697
Denominator for basic weighted average shares of common stock	57,274,315	55,576,200
Basic (loss) income per share of common stock	$ (0.02)	$ 0.02
Calculation of diluted loss per share of common stock:
Net (loss) income attributable to common stockholders	$ (1,306,954)	$ 851,697
Add: Income impact of assumed conversion of Debentures	0	0
Net (loss) income attributable to common stockholders plus assumed conversions	$ (1,306,954)	$ 851,697
Denominator for basic weighted average shares of common stock	57,274,315	55,576,200
Incremental shares from assumed conversions of Debentures payable	0	0
Denominator for diluted weighted average shares of common stock	57,274,315	55,576,200
Diluted (loss) income per share of common stock	$ (0.02)	$ 0.02

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details Textual) - $ / shares	3 Months Ended
	Sep. 30, 2015	Jan. 15, 2016	Jun. 30, 2015
Accounting Policies [Line Items]
Common Stock, Par Or Stated Value Per Share	$ 0.001		$ 0.001
Debt Instrument, Redemption, Description	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iii), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
Scenario, Forecast [Member]
Accounting Policies [Line Items]
Common Stock, Par Or Stated Value Per Share		$ 0.001
Convertible Debentures Shares Reserved For Future issuance		571,428
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 3.5
Convertible Preferred Stock, Shares Issued upon Conversion	14,000,000
Preferred Stock, Shares Issued	4,000,000		3,583,445
Common Stock [Member] | Series B Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	1,714,286
Debt Instrument, Convertible, Conversion Price	$ 3.50
Common Stock [Member] | Series C Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	952,381

Financial Condition (Details Te

Financial Condition (Details Textual) - USD ($)	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Jun. 30, 2014
Financial Condition [Line Items]
Cash and cash equivalents	$ 29,480,258	$ 31,467,748	$ 41,120,652	$ 36,696,892

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015
Research and development	$ 1,282,072	$ 811,107
Due to Related Parties	9,000,000		$ 9,000,000
Deferred interest payable - short term	166,667		166,667
Deferred interest payable - long term	291,666		333,333
Series B Convertible Debentures [Member]
Due to Related Parties	4,000,000		4,000,000
Series C Convertible Debenture [Member]
Due to Related Parties	5,000,000		5,000,000
TheraCour Pharma, Inc [Member]
Net Account Payable to related party	738,287		$ 316,196
Research and development	1,016,216	769,185
Due to Related Parties	$ 7,901	$ 110,578

Related Party Transactions (D33

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
Lab Supplies and Chemicals Fees	$ 25,000
Other General and Administrative Expense	2,000
Series B Convertible Debenture [Member]
Related Party Transaction [Line Items]
Interest Payable	4,000,000
Interest Expense, Debt	80,000	$ 80,000
Series C Convertible Debenture [Member]
Related Party Transaction [Line Items]
Interest Payable	5,000,000
Interest Expense, Debt	$ 125,000	$ 125,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Sep. 30, 2015	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Land	$ 260,000	$ 260,000
GMP Facility	7,979,202	7,905,938
Office Equipment	65,621	65,241
Furniture and Fixtures	1,400	1,400
Lab Equipment	5,524,292	5,264,272
Total Property and Equipment	13,830,515	13,496,851
Less Accumulated Depreciation	(1,695,809)	(1,534,203)
Property and Equipment, Net	$ 12,134,706	$ 11,962,648

Property and Equipment (Detai35

Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Property, Plant and Equipment [Line Items]
Depreciation	$ 161,606	$ 51,332

Trademark and Patents (Details)

Trademark and Patents (Details) - USD ($)	Sep. 30, 2015	Jun. 30, 2015
Trademarks And Patents [Line Items]
Trademarks and Patents	$ 458,954	$ 458,954
Less Accumulated Amortization	(61,284)	(59,217)
Trademarks and Patents, Net	$ 397,670	$ 399,737

Trademark and Patents (Details

Trademark and Patents (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Trademarks And Patents [Line Items]
Amortization	$ 2,067	$ 2,193
Trademark and Patents [Member]
Trademarks And Patents [Line Items]
Amortization	$ 2,067	$ 2,193

Convertible Debentures (Details

Convertible Debentures (Details) - Series B Debentures [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Proceeds	$ 6,000,000	$ 6,000,000
Debt discount for bifurcated derivative	(2,735,310)	(2,735,310)
Net Proceeds From Issuance Of Debt	3,264,690	3,264,690
Accumulated amortization of debt discount	1,619,521	1,435,892
Debenture payable - Series B, net	$ 4,884,211	$ 4,700,582

Convertible Debentures (Detai39

Convertible Debentures (Details 1) - Series C Debentures [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Proceeds	$ 5,000,000	$ 5,000,000
Net Proceeds From Issuance Of Debt	1,968,275	1,968,275
Accumulated amortization of debt discount	662,411	512,330
Debenture payable - Series C, net	2,630,686	2,480,605
Embedded Derivative Financial Instruments [Member]
Debt discount	(1,879,428)	(1,879,428)
Series A Preferred Stock [Member]
Debt discount	$ (1,152,297)	$ (1,152,297)

Convertible Debentures (Detai40

Convertible Debentures (Details Textual) - USD ($)	Jul. 02, 2014	Feb. 28, 2013	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015	Jan. 24, 2014	Sep. 12, 2013	Feb. 02, 2013
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)			$ 0.001		$ 0.001
Debt Conversion, Converted Instrument, Amount			$ 0	$ 1,646,606
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 6.05	$ 5.25
Debt Instrument, Redemption, Description			the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iii), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
Maximum [Member]
Debt Instrument [Line Items]
Share Price			$ 1.75
Minimum [Member]
Debt Instrument [Line Items]
Share Price			1.11
Restricted Stock [Member]
Debt Instrument [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance								571,429
Warrant [Member]
Debt Instrument [Line Items]
Investment Warrants, Exercise Price			$ 3.50
Debt Instrument, Term			3 years
Derivative Liability, Noncurrent			$ 2,475,893		$ 3,442,754
Series B Convertible Debentures [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)			183,629	157,728
Proceeds from Convertible Debt			$ 6,000,000		6,000,000
Debt Instrument, Term			4 years
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Warrants To Be Issued In Fourth Year								571,429
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3.50					$ 3.50
Debt Instrument, Redemption, Description		The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a shelf registration statement provided same is available, in accordance with the provisions of the Securities Act.
Long-term Debt, Excluding Current Maturities, Total			$ 6,000,000
Share Price			$ 1.19
Debt Instrument, Debt Default, Description of Violation or Event of Default			An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Projected Redemption Percentage Of Time			0.00%
Projected Annual Volatility Percentage			61.70%
Weighted Average Discount Rate, Percent			21.60%
Series B Convertible Debentures [Member] | Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Derivative Liability, Noncurrent			$ 82,503		366,764
Series B Convertible Debentures [Member] | Maximum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time			20.00%
Series B Convertible Debentures [Member] | Minimum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time			1.00%
Series B Convertible Debentures [Member] | Director [Member]
Debt Instrument [Line Items]
Proceeds from Convertible Debt			$ 4,000,000
Series A Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)			$ 150,081	$ 115,490
Debt Conversion, Converted Instrument, Shares Issued	187,000
Proceeds from Convertible Debt	$ 1,645,606
Repayments of Other Debt	1,152,297
Debt Instrument, Unamortized Discount	1,152,297
Debt Conversion, Converted Instrument, Amount	$ 1,879,428
Series C Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)	$ 0.001
Debt Instrument, Convertible, Conversion Price	$ 5.25
Debt Instrument, Convertible, Carrying Amount of Equity Component	$ 5,000,000
Redemption On Debentures	952,381
Warrants to purchase of Common Stock	619,048
Common stock exercise price	$ 6.05
Series C Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date			Jun. 30, 2018
Debt Instrument, Convertible, Conversion Price	$ 5.25
Investment Warrants, Exercise Price			$ 3.50
Proceeds from Issuance of Debt			$ 5,000,000		$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 6.05		$ 3.50
Share Price			$ 1.19		$ 1.75
Debt Instrument, Debt Default, Description of Violation or Event of Default			An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Projected Redemption Percentage Of Time			0.00%
Projected Annual Volatility Percentage			61.70%		62.00%
Weighted Average Discount Rate, Percent			21.60%		21.97%
Closing Common Stock Bid Price	$ 5.25
Additional Interest Rate For Warrants	7.00%
Series C Convertible Debenture [Member] | Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Derivative Liability, Noncurrent			$ 239,429		$ 476,289
Series C Convertible Debenture [Member] | Maximum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time			5.00%
Series C Convertible Debenture [Member] | Minimum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time			1.00%

Equity Transactions (Details)

Equity Transactions (Details)	3 Months Ended
	Sep. 30, 2015
Class of Stock [Line Items]
Expected life (year)	4 years
Expected volatility	58.39%
Expected annual rate of quarterly dividends	0.00%
Risk-free rate(s)	1.35%

Equity Transactions (Details Te

Equity Transactions (Details Textual) - USD ($)	1 Months Ended			3 Months Ended
	Oct. 30, 2015	Aug. 31, 2015	Jul. 21, 2015	Sep. 30, 2015	Jan. 24, 2014	Sep. 12, 2013
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 6.05	$ 5.25
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage				5.36%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				58.39%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.35%
Minimum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				1 year 7 months 17 days
Share Price				$ 1.11
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage				5.12%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				1 year 7 months 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions				27.74%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				60.40%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				0.27%
Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				2 years 11 months 8 days
Share Price				$ 1.75
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage				5.18%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				1 year 5 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions				39.78%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				62.21%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				0.39%
Warrant [Member]
Class of Stock [Line Items]
Number Of Common Stock To Be Issued Upon Conversion Of Warrants		17,148
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.50
Term Of Warrants		August, 2019
Warrants and Rights Outstanding		$ 8,745
Director [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				8,530
Share-based Compensation, Total				$ 11,250
Consulting Services [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				20,455
Share-based Compensation, Total				$ 27,000
Employee Compensation [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				1,295
Share-based Compensation, Total				$ 3,300
President [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			225,000
Share-based Compensation, Total				$ 77,336
Stock Issued During Period, Shares, Share-based Compensation, Gross				204,420
President [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			75,000
President [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years
Chief Executive Officer [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			225,000
Share-based Compensation, Total				$ 77,336
Stock Issued During Period, Shares, Share-based Compensation, Gross				204,420
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			75,000
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years
Subsequent Event [Member] | President [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	20,580
Subsequent Event [Member] | Chief Executive Officer [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	20,580
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				7,716
Share-based Compensation, Total				$ 27,850

Stock Options and Warrants (Det

Stock Options and Warrants (Details) - Stock Options [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	535,715
Number of Shares, Granted	0
Number of Shares, Exercised	313,155
Number of Shares, Expired	107,142
Number of Shares, Canceled	115,418
Number of Shares, Outstanding	0	535,715
Weighted Average Exercise Price per share , Outstanding	$ 0.35
Weighted Average Exercise Price per share, Granted	0
Weighted Average Exercise Price per share, Exercised	0
Weighted Average Exercise Price per share, Expired	0
Weighted Average Exercise Price per share, Canceled	0
Weighted Average Exercise Price per share , Outstanding	$ 0	$ 0.35
Weighted Average Remaining Contractual Term, (years) Granted	0 years
Weighted Average Remaining Contractual Term, (years) Exercised	0 years
Weighted Average Remaining Contractual Term, (years) Expired	0 years
Weighted Average Remaining Contractual Term, (years) Canceled	0 years
Weighted Average Remaining Contractual Term, (years) Outstanding	0 years	2 months 23 days
Aggregate Intrinsic Value, Outstanding	$ 2,094,643	$ 0
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Exercised	0
Aggregate Intrinsic Value, Expired	0
Aggregate Intrinsic Value, Canceled	$ 0

Stock Options and Warrants (D44

Stock Options and Warrants (Details 1) - Stock Warrants [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	5,976,675
Number of Shares, Granted	17,148
Number of Shares, Exercised	0
Number of Shares, Expired	0
Number of Shares, Canceled	0
Number of Shares, Outstanding	5,993,823	5,976,675
Weighted Average Exercise Price per share , Outstanding	$ 5.14
Weighted Average Exercise Price per share, Granted	1.5
Weighted Average Exercise Price per share, Exercised	0
Weighted Average Exercise Price per share, Expired	0
Weighted Average Exercise Price per share, Canceled	0
Weighted Average Exercise Price per share , Outstanding	$ 5.13	$ 5.14
Weighted Average Remaining Contractual Term, (years) Granted	3 years 9 months
Weighted Average Remaining Contractual Term, (years) Exercised	0 years
Weighted Average Remaining Contractual Term, (years) Expired	0 years
Weighted Average Remaining Contractual Term, (years) Canceled	0 years
Weighted Average Remaining Contractual Term, (years) Outstanding	2 years 11 months 12 days	3 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 19,000
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Exercised	0
Aggregate Intrinsic Value, Expired	0
Aggregate Intrinsic Value, Cancelled	0
Aggregate Intrinsic Value, Outstanding	$ 4	$ 19,000

Stock Options and Warrants (D45

Stock Options and Warrants (Details Textual)	3 Months Ended
	Sep. 30, 2015shares
June 30, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	345,713
Warrants Expiration Date	Jun. 30, 2016
June 30, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,571
Warrants Expiration Date	Jun. 30, 2017
June 30, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,577
Warrants Expiration Date	Jun. 30, 2018
June 30, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	5,493,814
Warrants Expiration Date	Jun. 30, 2019
June 30, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	17,148
Warrants Expiration Date	Jun. 30, 2020

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($)	Sep. 30, 2015	Jun. 30, 2015
Warrant [Member]
Derivative Liability, Noncurrent	$ 2,475,893	$ 3,442,754
Fair Value, Inputs, Level 1 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative Liability, Noncurrent	2,797,825	4,285,808
Fair Value, Inputs, Level 3 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	82,503	366,764
Fair Value, Inputs, Level 3 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	239,429	476,289
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	$ 2,475,893	$ 3,442,754

Fair Value Measurement (Detai47

Fair Value Measurement (Details 1)	3 Months Ended
	Sep. 30, 2015
One year ended 6/30/2015
Fair Value Assumptions, Expected Volatility Rate	62.00%
One year ended 9/30/2015
Fair Value Assumptions, Expected Volatility Rate	62.00%

Fair Value Measurement (Detai48

Fair Value Measurement (Details 2)	3 Months Ended
	Sep. 30, 2015USD ($)
Warrant [Member]
Begining Balance	$ 3,442,754
Additions during the year	0
Change in fair value	(966,861)
Transfer in and/or out of Level 3	0
Ending Balance	2,475,893
Derivative liability - Series C debentures [Member]
Begining Balance	476,289
Additions during the year	0
Change in fair value	(236,860)
Transfer in and/or out of Level 3	0
Ending Balance	239,429
Derivative liability - Series B debentures [Member]
Begining Balance	366,764
Additions during the year	0
Change in fair value	(284,261)
Transfer in and/or out of Level 3	0
Ending Balance	$ 82,503

Fair Value Measurement (Detai49

Fair Value Measurement (Details Textual) - $ / shares	1 Months Ended
	Jan. 24, 2014	Sep. 12, 2013	Sep. 30, 2015
Class of Warrant or Right, Outstanding	2,379,935	2,910,071	5,425,222
Warrants Issued	2,479,935	2,945,428
Warrant Expiration Term		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.05	$ 5.25
Placement Agents [Member]
Warrants Issued	76,306	58,910

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Commitments and Contingencies [Line Items]
Operating Leases, Rent Expense, Net	$ 0	$ 26,085